Dowson Andrew J, Tepper Stewart J, Dahlöf Carl
King's Headache Service, King's College Hospital, Denmark Hill, London SE5 9RS, UK.
J Headache Pain. 2005 Jun;6(3):112-20. doi: 10.1007/s10194-005-0164-3. Epub 2005 May 13.
Oral triptans are effective and well tolerated acute treatments for migraine, but clinical differences between them are small and difficult to measure in conventional clinical trials. Patient preference assesses a global measure of efficacy and tolerability, and may be a more sensitive means of distinguishing between these drugs. In a series of studies, patients consistently expressed a clear preference for triptans over their usual non-triptan acute medications, e.g., analgesics and ergotamine. Direct comparator studies of patient preference with oral triptans showed that patients could distinguish between different triptans, and between different formulations of the same triptan. Patients could even distinguish between the three oral doses of sumatriptan. The most frequently provided reasons for preference were speed of response and overall effectiveness. Patient preference is a sensitive clinical trial endpoint and physicians should consider using it when reviewing the efficacy of acute migraine medications.
口服曲坦类药物是治疗偏头痛有效的急性治疗药物，耐受性良好，但它们之间的临床差异较小，在传统临床试验中难以衡量。患者偏好评估了疗效和耐受性的整体指标，可能是区分这些药物的更敏感方法。在一系列研究中，患者始终明确表示比起常用的非曲坦类急性药物（如镇痛药和麦角胺），他们更喜欢曲坦类药物。口服曲坦类药物的患者偏好直接比较研究表明，患者能够区分不同的曲坦类药物，以及同一曲坦类药物的不同剂型。患者甚至能够区分舒马曲坦的三种口服剂量。最常给出的偏好原因是起效速度和总体疗效。患者偏好是一个敏感的临床试验终点，医生在评估急性偏头痛药物的疗效时应考虑使用这一指标。
